A detailed history of Jane Street Group, LLC transactions in Annovis Bio, Inc. stock. As of the latest transaction made, Jane Street Group, LLC holds 20,206 shares of ANVS stock, worth $101,030. This represents 0.0% of its overall portfolio holdings.

Number of Shares
20,206
Previous 10,123 99.6%
Holding current value
$101,030
Previous $58,000 179.31%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$5.27 - $15.46 $53,137 - $155,883
10,083 Added 99.6%
20,206 $162,000
Q2 2024

Aug 14, 2024

BUY
$4.82 - $18.01 $48,792 - $182,315
10,123 New
10,123 $58,000
Q4 2023

Feb 14, 2024

BUY
$5.55 - $19.62 $66,427 - $234,831
11,969 New
11,969 $223,000
Q1 2023

May 15, 2023

BUY
$12.33 - $22.1 $183,347 - $328,627
14,870 New
14,870 $229,000

Others Institutions Holding ANVS

About Annovis Bio, Inc.


  • Ticker ANVS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 8,163,920
  • Market Cap $40.8M
  • Description
  • Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...
More about ANVS
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.